News

Learn how leading pharmaceutical, biotech, contract research organizations and health authorities are transforming Regulatory Affairs

ArisGlobal, a leading life sciences technology provider, announced that China-based Fosun Pharma has selected LifeSphere Safety MultiVigilance (LSMV) as its global pharmacovigilance system.

ArisGlobal Safety Experts to Present “Supporting Life Science Industry to Meet the New Regulation Challenges” at 9th Asia Pharma R&D Leaders – Pharma & Healthcare

The U.S. Food and Drug Administration (FDA) has selected Booz Allen Hamilton to support development, modernization, and enhancement of the FDA Adverse Event Reporting System (FAERS). As part of this work, the Agency will deploy ArisGlobal’s LifeSphere MultiVigilance (LSMV) platform to replace part of its current pharmacovigilance system that will intake, triage and process safety reports and make them available for review and analysis.

There are a myriad potential uses of AI for Medical Information and pharmcovigilance, and if you don’t have an AI strategy you will be left behind. AI will allow us to automate.....

ArisGlobal announced that the health authority (HA) of the largest country in East Asia has selected and implemented LifeSphere Safety MultiVigilance (also known as ARISc) solution for clinical safety and pharmacovigilance (PV) through its local partner.

LifeSphere Safety MultiVigilance (LSSMV) database system has auto-translation capabilities that can translate safety narratives from English to Chinese and vice versa using advanced machine-learning technology.

Major regulatory reforms for drugs and medical devices are being initiated in China to ensure safe, innovative, effective and high-quality medicinal products are available to its population. As part of this initiative

ArisGlobal, a leading life sciences technology provider, announced the launch of LifeSphere MultiVigilance – the next-generation platform for individual case safety report (ICSR) intake powered by LifeSphere Nava – ArisGlobal’s cognitive computing engine.

In order to stay compliant with NMPA requirements (submitting all post-marketing ADRs in ICH E2B (R3) format), drug manufacturers are required to procure an electronic safety database that is.....